Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved Accrufer, ferric maltol capsules, to treat iron deficiency in pediatric patients ages 10 and older.
Accrufer had previously been approved for adults, and the pediatric indication gives clinicians another prescription oral option for older children and adolescents.
Iron deficiency is common and can affect development, energy and health, so route, tolerability and access matter.
Why It Matters
Pediatric label expansions can widen access to therapies for common conditions, not only rare diseases.
What to Watch
Watch adoption, tolerability data and payer coverage for pediatric use.
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAIron DeficiencyPediatricsDrug Approval